kynureninase inhibitor (St Andrews University)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namekynureninase inhibitor (St Andrews University)
Drug Alias Nameneurodegeneration therapy (St Andrews University)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate [NMDA] receptor antagonists
TargetsGlutamate [NMDA] receptor
Therapy Area/IndicationsAlzheimer DiseaseDementiaParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of St. Andrews
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of St. Andrews
Active IndicationsN/A
Inactive IndicationsAlzheimer DiseaseDementiaParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A